CoreValve gets early approval

Investor's Business Daily
January 2014
Investors Business Daily;1/21/2014, pA02
The artificial heart valve by


Related Articles

  • Medtronic Wins Early CoreValve Approval; Edwards Down. AMY REEVES // Investors Business Daily;1/17/2014, p00 

    The FDA approved

  • Consultant sees 'graveyard of companies FDA has killed.'. McCARTY, MARK // Medical Device Daily;7/25/2011, Vol. 15 Issue 137, p1 

    This article reports on an advisory committee recommendation received by Edwards Lifesciences from the U.S. Food and Drug Administration (FDA) for its Sapien transcatheter aortic valve in 2011. The prices of the company's shares dropped despite the recommendation. The FDA asked for two...

  • Medtronic Completes Enrollment of Extreme Risk Patient Group in CoreValve(r) U.S. Pivotal Trial.  // Biomedical Market Newsletter;1/28/2012, Vol. 21, p1 

    The article informs that Medtronic Inc. has completed the enrollment of extreme risk patients (ERP) in its CoreValve U.S. Pivotal Trial. The CoreValve system has been designed by the company to replace diseased aortic valves in patients with severe aortic stenosis without open heart surgery. The...

  • Medtronic, Edwards face off. Investor's Business Daily // Investors Business Daily;4/ 1/2014, pA02 

    The medical device giants offered competing sets of data on their artificial heart valves over the weekend.

  • Edwards Lifesciences Revenue Miss Jolts Investors. KREY, MICHAEL // Investors Business Daily;10/26/2016, p1 

    The article informs that stocks of heart valve maker Edwards Lifesciences decreased to a four-month low on October 26, 2016 after posting the third quarter revenue that missed Wall Street expectations. It is noted the firm has won European approval to expand the use of its Sapien 3 heart valve...

  • Edwards Gets Nod from Panel; Talk of Stroke Threat Cools Shares. Reed, Vita // Orange County Business Journal;7/25/2011, Vol. 34 Issue 30, p10 

    The article reports on the decision of a U.S. Food and Drug Administration (FDA) panel over Edwards Sapien valve from Edwards Lifesciences Corp. for patients with severe aortic valve.

  • FDA Gives Go-Ahead for Trial of Edwards' Intuity. Reed, Vita // Orange County Business Journal;7/16/2012, Vol. 35 Issue 29, p48 

    The article reports on the conditional exemption given by the U.S. Food and Drug Administration (FDA) to allow Edwards Lifesciences Corp. to conduct a multicenter clinical trial for Edwards' Intuity device.

  • Sapien XT approved for high-risk, inoperable patients.  // Cardiology Today;Aug2014, Vol. 17 Issue 8, p1 

    The article reports on the approval granted by the U.S. Food and Drug Administration (FDA) to Edward Lifesciences' Sapien XT valve, which is used to treat high-risk and inoperable patients with severe aortic stenosis.

  • Edwards initiates TRANSFORM study for Intuity valve system.  // Medical Device Daily;7/3/2012, Vol. 16 Issue 128, p9 

    The article reports on the conditional investigational Device Exemption (IDE) received by Irvine, California-based Edwards Lifesciences from the U.S. Food and Drug Administration to initiate the TRANSFORM trial.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics